HBOT Conversations:
Dr. Paul Harch & Birth Injuries/ Cerebral Palsy
Dr. Paul G. Harch, M.D. has used hyperbaric oxygen therapy to treat more than 100 different conditions, including stroke, dementia, autism, and traumatic brain injury. His goal is to help his patients get their lives back using hyperbaric oxygen therapy.
He is the author of The Oxygen Revolution and is considered an International expert and pioneer in the field of Hyperbaric Oxygen Therapy (HBOT). His informative, and comprehensive guide on HBOT has helped countless souls better understand what HBOT is and how it directly affects the body at the genetic level.
This episode on birth injuries with a strong focus on Cerebral Palsy (CP) is the fifth in a nine episode series that will be released weekly with Dr. Harch.
Watch the Podcast
In episode 5 of 9, host Edward di Girolamo speaks with world renowned HBOT expert, Dr. Paul G. Harch about birth injuries and Cerebral Palsy (Chapter 5 of his book, The Oxygen Revolution).
In Dr. Harch’s book he describes the trip down the birth canal as one of the most high-risk journeys any human will ever make. Dr. Harch educates us on how traumatic birth experiences can trigger Cerebral Palsy diagnoses in young infants, and how premature babies are at great risk for Cerebral Palsy since they are born with the center of the brain undeveloped, still very fragile and prone to spontaneous bleeding.
Every day desperate parents around the world seek alternative healing therapies for their children with cerebral palsy. Dr. Harch dives deep into the use of Hyperbaric Oxygen Therapy (HBOT) for the treatment of Cerebral Palsy and other neurological birth disorders, and explains the reasons why parents should embrace this therapy. Essentially, Dr. Harch describes Cerebral Palsy as a wound to the brain, so it should respond to Hyperbaric Oxygen Therapy the same way as other brain injuries. He confers that it absolutely does.
Dr. Harch reveals success stories of CP children who have had found hope and new life from Hyperbarics. In response to these stories and hearing that it works to heal and ease life-long debilitating CP symptoms, di Girolamo wants to know why more parents aren’t seeking out HBOT to help their cerebral palsy children? Harch relays that there’s too much inconsistent medical literature out there, and in many ways it’s just plain wrong. For example, a parent asks their doctor, “How about HBOT to treat Cerebral Palsy?”— the doctor might be unfamiliar with the therapy, so he/she checks the online medical database for HBOT and CP. Unfortunately this doctor will likely find some skewed data, leading the doctor to respond with “so….. I don’t think it’ll help”. Although, as Dr. Harch explains, the exact opposite is what’s true; HBOT absolutely helps CP patients.
One example given is that a well respected peer-reviewed medical journal, The Lancet, published medical literature on HBOT and CP announcing there was no proven benefit to use Hyperbaric Oxygen Therapy to treat Cerebral Palsy. But, the inconsistency there was that the control group was defined as a placebo, and that was not right. In response, Dr. Pierre Marois and his team, released a retrospective study on HBOT in the treatment of Cerebral Palsy that showed studies and numerous reports demonstrating the positive effects of Hyperbaric Oxygen Therapy (HBOT) in children with Cerebral Palsy.
Dr. Harch suggests our viewers dive into his 2021 presentation at the Team Luke3 Hope for Minds pediatric brain injury conference. Dr. Harch provided a summarization of all of the science showing that Hyperbaric Oxygen Therapy had extremely positive effects on every stage of the stem cell process. Additionally, Dr. Proefrock’s presentation from the same conference, “Current Trends in Naturopathic Treatment of Pediatric Neurological Injury” reveals stem cell data for children in the midst of HBOT treatment; showing that the children who have had Hyperbaric treatments produced 4x the amount of stem cells compared to those who did not.
Dr. Harch explains the roadblock for using Hyperbaric Oxygen for treatment of CP is still extremely difficult to get around, and he references the 2012 article by Novak and Badawai, Last breath: effectiveness of hyperbaric oxygen treatment for Cerebral Palsy as an example. In this article, they concluded that “Hyperbaric Oxygen does not have a clinically important effect on gross motor and self-care function in children with Cerebral Palsy.” Dr. Harch clarifies why they were wrong on the science, and how information like that is what’s preventing the average medical doctor to recommend HBOT for Cerebral Palsy.
di Girolamo and Dr. Harch urges viewers to find out for themselves if HBOT could be a good therapy for them or their loved one(s) living with CP. If you would like to dive into the world of Hyperbaric Oxygen Therapy for the treatment of Cerebral Palsy, HBOT News encourages you to find a licensed Hyperbaric Oxygen Therapy facility with hard mono-chambers or hard multi-place chambers, and act on this responsibly. Just like anything in the world of modern medicine, you can be injured or do more harm than good if HBOT is not administered correctly.
All of the data and success stories Dr. Harch reveals paints a much different picture than what the medical industry is showing us. Go try Hyperbaric Oxygen Therapy sooner than later to treat, heal, and ease the symptoms of Cerebral Palsy. We trust that HBOT can also change your life!
Subscribe Now, It’s Free !
Guest
Dr. Paul G. Harch, MD
Dr. Harch initiated and continues to be a private practice that has resulted in the largest case experience in neurological hyperbaric medicine in the world. In this practice, he adapted the concepts of conventional hyperbaric oxygen therapy to wounds in the central nervous system, which spawned the subsequent academic and research practice. Harch HBOT is the best place to receive oxygen therapy treatments, and patients have traveled from more than 50 countries to be treated by Dr. Harch himself.
Harch HBOT – Hyperbaric Oxygen Therapy Clinic
5216 Lapalco Blvd.
Marrero, LA
504-309-4948
hbot@hbot.com
https://hbot.com/
Recent HBOT News
Healing under pressure: Inside a military hyperbaric chamber
At 16, she had a stroke. At 17, her town burned in the Camp Fire. Now, as her community rebuilds, she's healing thanks to hyperbaric therapy. SACRAMENTO, Calif — February 2, 2017, started off as an ordinary day for the Pipkin Family. Patrick and Stacey Pipkin just...
Clinical Trial – High-flow Oxygen for Vaso-occlusive Pain Crisis
Sickle cell disease (SCD) is characterized by recurrent vaso-occlusive pain crisis (VOC),
which may evolve to acute chest syndrome (ACS), the most common cause of death among adult
patients with SCD. Currently, there is no safe and effective treatment to abort VOC or
prevent secondary ACS. Management of VOC mostly involve a symptomatic approach including
hydration, analgesics, transfusion, and incentive spirometry, which was investigated in a
very limited number of patients (<30).
The polymerisation of HbS is one major feature in the pathogenesis of vaso-occlusion. Among
factors determining the rate and extent of HbS polymer formation, the hypoxic stimulus is one
of the most potent and readily alterable. Current guidelines recommend oxygen therapy in
patients with VOC in order to maintain a target oxygen saturation of 95%. Low-flow nasal
oxygen (LFNO) is routinely used to achieve this normoxia approach, particularly in patients
at risk of secondary ACS because they may experience acute desaturation. In contrast, various
case series suggest a potential beneficial role of intensified oxygen therapy targeting
hyperoxia for the management of VOC, particularly with the use of hyperbaric oxygen, but the
latter is difficult to implement in routine clinical practice.
A recent high-flow nasal oxygen (HFNO) technology allows the delivery of humidified gas at
high fraction of inspired oxygen (FiO2) through nasal cannula. The FiO2 can be adjusted up to
100% (allowing hyperoxia that may reverse sickling) and the flow can be increased up to 60
L/min (which generates positive airway pressure and dead space flushing, that may prevent
evolution of VOC towards ACS by alleviating atelectasis and opioid-induced hypercapnia). In
patients with acute respiratory failure, HFNO has been shown to improve patient's comfort,
oxygenation, and survival as compared to standard oxygen or non-invasive ventilation.
The aim of the present study is to test the efficacy and safety of HFNO for the management of
VOC and prevention of secondary ACS. The investigators will use a multi-arm multi-stage
(MAMS) design to achieve these goals. HFNO will be delivered through AIRVO 2 (Fisher and
Paykel Healthcare, New Zealand), a device that incorporates a turbine allowing its use in
hospital wards.
Clinical Trial – Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
Subjects with Acute Myeloblastic Leukemia (AML) and myelodysplastic syndrome (MDS) who are
considered eligible for allogeneic stem cell transplant by the transplant team at WCI (Wilmot
Cancer Institute)will be enrolled in the study. Patients will receive Melphalan on day -2 and
HBO (Hyperbaric Oxygen) therapy on day 0 of the transplant. After neutrophil recovery is
documented, the patients will be seen in clinic at least weekly through day +100.